Using 68Ga-NY104 PET/CT to guide radiation therapy for advanced kidney cancer
Effect of 68Ga-NY104 and 18F-FDG PET/CT Guided Radiation Therapy Combined with Systemic Treatment in Patients with Clear Cell Renal Cell Carcinoma.
This study is testing if a special imaging technique can help doctors better plan radiation therapy for people with advanced kidney cancer to improve their treatment outcomes.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06613269 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of using 68Ga-NY104 PET/CT imaging to guide radiation therapy in patients with advanced clear cell renal cell carcinoma (ccRCC). The approach combines targeted imaging with radiation treatment and standard systemic therapy to improve outcomes for patients with metastatic or recurrent ccRCC. The study aims to evaluate the diagnostic efficacy of the CAIX-targeted PET tracer and its impact on treatment response. Participants will undergo imaging and receive radiation therapy based on the results, with the goal of enhancing therapeutic effectiveness.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed clear cell renal cell carcinoma who are eligible for radiation therapy.
Not a fit: Patients with brain metastasis, other uncontrolled malignancies, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes for patients with advanced clear cell renal cell carcinoma.
How similar studies have performed: Previous studies have shown promising outcomes with similar approaches combining radiation therapy and systemic therapy in metastatic ccRCC.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old * Histologically or cytologically confirmed clear cell renal cell carcinoma * Eligible for radiation therapy: no more than 10 lesions in total * Expected survival: over 3 months * ECOG: 0 or 1 * Sufficient organ function * Written informed consent Exclusion Criteria: * Brain metastasis/carcinomatous meningitis * Other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer. * Pregnant or breastfeeding. * Active infection.
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xianshu Gao, MD
- Email: gao7777@139.com
- Phone: +86 01083575641
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.